Pulse Biosciences, Inc. (PLSE)
USD 17.83
(-7.33%)
USD 17.83
(-7.33%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -43.57 Million USD | 24.95% |
| 2022 | -58.05 Million USD | 7.87% |
| 2021 | -63.01 Million USD | -26.12% |
| 2020 | -49.96 Million USD | -4.19% |
| 2019 | -47.95 Million USD | -26.32% |
| 2018 | -37.96 Million USD | -47.06% |
| 2017 | -25.81 Million USD | -169.29% |
| 2016 | -9.58 Million USD | -114.55% |
| 2015 | -4.46 Million USD | -1347.95% |
| 2014 | -308.57 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -13.65 Million USD | -16.45% |
| 2024 Q2 | -11.72 Million USD | -10.47% |
| 2024 Q1 | -10.61 Million USD | 15.3% |
| 2023 FY | -43.57 Million USD | 24.95% |
| 2023 Q4 | -12.53 Million USD | -11.38% |
| 2023 Q3 | -11.25 Million USD | -10.02% |
| 2023 Q1 | -9.56 Million USD | -9.34% |
| 2023 Q2 | -10.22 Million USD | -6.95% |
| 2022 Q3 | -18.02 Million USD | -28.62% |
| 2022 Q2 | -14.01 Million USD | 18.87% |
| 2022 FY | -58.05 Million USD | 7.87% |
| 2022 Q1 | -17.27 Million USD | -12.09% |
| 2022 Q4 | -8.74 Million USD | 51.48% |
| 2021 Q2 | -14.8 Million USD | 20.08% |
| 2021 Q4 | -15.41 Million USD | -7.97% |
| 2021 Q1 | -18.52 Million USD | -34.67% |
| 2021 FY | -63.01 Million USD | -26.12% |
| 2021 Q3 | -14.27 Million USD | 3.6% |
| 2020 Q4 | -13.75 Million USD | -6.59% |
| 2020 Q1 | -11.95 Million USD | 14.21% |
| 2020 Q2 | -11.35 Million USD | 4.99% |
| 2020 Q3 | -12.9 Million USD | -13.66% |
| 2020 FY | -49.96 Million USD | -4.19% |
| 2019 Q1 | -10.41 Million USD | -14.9% |
| 2019 FY | -47.95 Million USD | -26.32% |
| 2019 Q4 | -13.93 Million USD | -16.43% |
| 2019 Q3 | -11.96 Million USD | -2.7% |
| 2019 Q2 | -11.64 Million USD | -11.9% |
| 2018 Q3 | -10.87 Million USD | -16.98% |
| 2018 Q2 | -9.3 Million USD | -6.6% |
| 2018 FY | -37.96 Million USD | -47.06% |
| 2018 Q1 | -8.72 Million USD | 1.21% |
| 2018 Q4 | -9.06 Million USD | 16.72% |
| 2017 Q2 | -6.22 Million USD | -92.18% |
| 2017 Q1 | -3.23 Million USD | -13.86% |
| 2017 Q3 | -7.52 Million USD | -20.96% |
| 2017 Q4 | -8.83 Million USD | -17.36% |
| 2017 FY | -25.81 Million USD | -169.29% |
| 2016 Q1 | -1.68 Million USD | -9.71% |
| 2016 FY | -9.58 Million USD | -114.55% |
| 2016 Q4 | -2.84 Million USD | -1.61% |
| 2016 Q3 | -2.79 Million USD | -23.75% |
| 2016 Q2 | -2.26 Million USD | -34.26% |
| 2015 Q4 | -1.53 Million USD | -24.39% |
| 2015 Q1 | -743 Thousand USD | -140.86% |
| 2015 Q3 | -1.23 Million USD | -29.08% |
| 2015 FY | -4.46 Million USD | -1347.95% |
| 2015 Q2 | -956 Thousand USD | -28.67% |
| 2014 Q4 | -308.47 Thousand USD | 0.0% |
| 2014 FY | -308.57 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Akoya Biosciences, Inc. | -57.66 Million USD | 24.44% |
| AngioDynamics, Inc. | -97.71 Million USD | 55.408% |
| AtriCure, Inc. | -26.68 Million USD | -63.302% |
| Avinger, Inc. | -16.63 Million USD | -161.942% |
| Azenta, Inc. | -73.12 Million USD | 40.412% |
| BioLife Solutions, Inc. | -70.82 Million USD | 38.477% |
| The Cooper Companies, Inc. | 533.1 Million USD | 108.174% |
| Daxor Corporation | -177.07 Thousand USD | -24507.652% |
| Ekso Bionics Holdings, Inc. | -15.11 Million USD | -188.34% |
| Femasys Inc. | -14.5 Million USD | -200.336% |
| GlucoTrack, Inc. | -7.1 Million USD | -513.373% |
| Harvard Bioscience, Inc. | 1.89 Million USD | 2400.634% |
| Hologic, Inc. | 882.6 Million USD | 104.937% |
| ICU Medical, Inc. | 22.82 Million USD | 290.905% |
| Intuitive Surgical, Inc. | 1.76 Billion USD | 102.466% |
| KORU Medical Systems, Inc. | -10.26 Million USD | -324.285% |
| LeMaitre Vascular, Inc. | 37.08 Million USD | 217.507% |
| Innovative Eyewear, Inc. | -6.9 Million USD | -531.458% |
| Innovative Eyewear, Inc. | -6.9 Million USD | -531.458% |
| Masimo Corporation | 136.5 Million USD | 131.922% |
| Microbot Medical Inc. | -9.85 Million USD | -342.151% |
| Meihua International Medical Technologies Co., Ltd. | 14.67 Million USD | 396.928% |
| Merit Medical Systems, Inc. | 123.94 Million USD | 135.156% |
| Nephros, Inc. | -1.59 Million USD | -2635.342% |
| NovoCure Limited | -232.87 Million USD | 81.288% |
| NEXGEL, Inc. | -3.47 Million USD | -1153.207% |
| NEXGEL, Inc. | -3.47 Million USD | -1153.207% |
| Singular Genomics Systems, Inc. | -102.8 Million USD | 57.613% |
| OraSure Technologies, Inc. | 54.07 Million USD | 180.575% |
| Pro-Dex, Inc. | 7.17 Million USD | 707.472% |
| Predictive Oncology Inc. | -13.92 Million USD | -213.002% |
| Precision Optics Corporation, Inc. | -2.72 Million USD | -1499.437% |
| QuidelOrtho Corporation | 139.1 Million USD | 131.326% |
| Repligen Corporation | 54.57 Million USD | 179.841% |
| Sanara MedTech Inc. | -4.21 Million USD | -933.747% |
| STAAR Surgical Company | 28.09 Million USD | 255.084% |
| Sharps Technology, Inc. | -10.12 Million USD | -330.29% |
| Utah Medical Products, Inc. | 16.77 Million USD | 359.725% |
| DENTSPLY SIRONA Inc. | -85 Million USD | 48.736% |
| Jin Medical International Ltd. | 2.86 Million USD | 1619.708% |